Telemedicine consult for Brain Diseases

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Brain Diseases+1 More
Telemedicine consult - DiagnosticTest
Eligibility
< 18
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing whether telemedicine can help doctors diagnose newborns with encephalopathy, a key factor in deciding whether to treat them with therapeutic hypothermia.

Eligible Conditions
  • Brain Diseases
  • Neonatal Encephalopathy

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: First 10 days of life

Day 10
Combined outcome of seizure or brain Injury on imaging

Trial Safety

Safety Progress

1 of 3

Trial Design

1 Treatment Group

Telemedicine arm
1 of 1

Experimental Treatment

150 Total Participants · 1 Treatment Group

Primary Treatment: Telemedicine consult · No Placebo Group · N/A

Telemedicine arm
DiagnosticTest
Experimental Group · 1 Intervention: Telemedicine consult · Intervention Types: DiagnosticTest

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: first 10 days of life

Who is running the clinical trial?

MaineHealthLead Sponsor
63 Previous Clinical Trials
38,486 Total Patients Enrolled
4 Trials studying Brain Diseases
66 Patients Enrolled for Brain Diseases
Alexa K Craig, MDPrincipal Investigatorphysician
1 Previous Clinical Trials
34 Total Patients Enrolled
1 Trials studying Brain Diseases
34 Patients Enrolled for Brain Diseases

Eligibility Criteria

Age < 18 · All Participants · 5 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have a primary pulmonary process.
Umbilical cord pH 7.01 to 7.
The umbilical cord pH is less than 7.0 or the base deficit is greater than -16.
You have a 10-minute Apgar score of < 5.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 6th, 2021

Last Reviewed: November 26th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.